1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 INTRODUCTION
2.2 SCOPE OF STUDY
2.3 RESEARCH OBJECTIVE
2.4 ASSUMPTIONS & LIMITATIONS
2.4.1 ASSUMPTIONS
2.4.2 LIMITATIONS
2.5 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 INCREASING POOR HEALTH CONDITIONS IS MAJOR CAUSE FOR FEMALE-SPECIFIC HEALTH ISSUES
4.2.2 GROWING EMPHASIS ON PREVENTIVE CARE SERVICES
4.2.3 INITIATIVES TAKEN TO PROMOTE WOMEN HEALTHCARE
4.2.4 INCREASE IN R&D ACTIVITIES BY MAJOR PLAYERS FOR WOMEN HEALTH
4.3 RESTRAINTS
4.3.1 HIGH COST OF DIAGNOSIS
4.3.2 HIGH COST OF TREATMENT
4.4 OPPORTUNITIES
4.4.1 EARLY DIAGNOSIS OF THE WOMEN HEALTH DISEASES
4.4.2 RISING AWARENESS FOR WOMEN HEALTH IN EMERGING NATIONS
4.5 CHALLENGE
4.5.1 CHALLENGES TO ACCESSING CARE
5 MARKET FACTOR ANALYSIS
5.1 PORTERS FIVE FORCES MODEL
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF RIVALRY
5.2 VALUE CHAIN ANALYSIS
5.2.1 RESEARCH & DEVELOPMENT (R&D)
5.2.2 OPERATIONS
5.2.3 COMMERCIAL OPERATIONS AND DISTRIBUTION & PHARMACIES
5.2.4 CONSUMERS
6 GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION
6.1 INTRODUCTION
6.2 POSTMENOPAUSAL OSTEOPOROSIS
6.3 INFERTILITY
6.4 REPRODUCTIVE HEALTH MANAGEMENT
6.5 POLYCYSTIC OVARY SYNDROME
6.6 GYNECOLOGIC CANCER
6.7 OTHER INDICATIONS
7 WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
7.1 INTRODUCTION
7.2 DIAGNOSIS
7.3 TREATMENT
8 WOMEN HEALTHCARE MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS & CLINICS
8.3 GYNECOLOGY CENTERS
8.4 RESEARCH INSTITUTES
8.5 OTHER END USER
9 GLOBAL WOMEN HEALTHCARE MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.2.1 THE U.S.
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.2.2 CANADA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3 EUROPE
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.1 GERMANY
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.2 FRANCE
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.3 UK
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.4 ITALY
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.5 SPAIN
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.3.6 REST OF EUROPE
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4 ASIA-PACIFIC
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4.1 JAPAN
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4.2 CHINA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4.3 INDIA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4.4 REPUBLIC OF KOREA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.4.5 REST OF ASIA-PACIFIC
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.5.1 UAE
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.5.2 SAUDI ARABIA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.5.3 EGYPT
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
9.5.4 REST OF MIDDLE EAST & AFRICA
WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT
WOMEN HEALTHCARE MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
11 COMPANY PROFILE
11.1 ALLERGAN PLC.
11.1.1 OVERVIEW
11.1.2 PRODUCT OVERVIEW
11.1.3 FINANCIALS
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.2 AMGEN
11.2.1 COMPANY OVERVIEW
11.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
11.2.3 FINANCIAL OVERVIEW
11.2.4 KEY DEVELOPMENT
11.2.5 SWOT ANALYSIS
11.3 BAYER AG
11.3.1 OVERVIEW
11.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
11.3.3 FINANCIAL UPDATES
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.4 BECTON, DICKINSON AND COMPANY
11.4.1 OVERVIEW
11.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
11.4.3 FINANCIAL UPDATES
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.5 ELI LILLY COMPANY
11.5.1 COMPANY OVERVIEW
11.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
11.5.3 FINANCIAL OVERVIEW
11.5.4 KEY DEVELOPMENT
11.5.5 SWOT ANALYSIS
11.6 MERCK & CO., INC.
11.6.1 OVERVIEW
11.6.2 PRODUCT OVERVIEW
11.6.3 FINANCIALS
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.7 PFIZER INC.
11.7.1 OVERVIEW
11.7.2 PRODUCT OVERVIEW
11.7.3 FINANCIALS
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
11.8.1 COMPANY OVERVIEW
11.8.2 PRODUCT OVERVIEW
11.8.3 FINANCIAL OVERVIEW
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
12 List Of Tables
TABLE 1 GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 29
TABLE 2 POSTMENOPAUSAL OSTEOPOROSIS MARKET, BY REGION, 2023-2030 (USD MILLION) 31
TABLE 3 INFERTILITY MARKET, BY REGION, 2023-2030 (USD MILLION) 32
TABLE 4 REPRODUCTIVE HEALTH MANAGEMENT MARKET, BY REGION, 2023-2030 (USD MILLION) 33
TABLE 5 POLYCYSTIC OVARY SYNDROME MARKET, BY REGION, 2023-2030 (USD MILLION) 34
TABLE 6 GYNECOLOGIC CANCER MARKET, BY REGION, 2023-2030 (USD MILLION) 35
TABLE 7 OTHER INDICATIONS MARKET, BY REGION, 2023-2030 (USD MILLION) 36
TABLE 8 GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 37
TABLE 9 DIAGNOSIS MARKET, BY REGION, 2023-2030 (USD MILLION) 39
TABLE 10 TREATMENT MARKET, BY REGION, 2023-2030 (USD MILLION) 40
TABLE 11 GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 41
TABLE 12 HOSPITALS & CLINICS MARKET, BY REGION, 2023-2030 (USD MILLION) 43
TABLE 13 GYNECOLOGY CENTERS MARKET, BY REGION, 2023-2030 (USD MILLION) 44
TABLE 14 RESEARCH INSTITUTES MARKET, BY REGION, 2023-2030 (USD MILLION) 45
TABLE 15 OTHER END USER MARKET, BY REGION, 2023-2030 (USD MILLION) 46
TABLE 16 GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2023-2030 (USD MILLION) 47
TABLE 17 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 49
TABLE 18 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 50
TABLE 19 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 51
TABLE 20 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 52
TABLE 21 U.S. WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 52
TABLE 22 U.S. WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 53
TABLE 23 U.S. WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 54
TABLE 24 CANADA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 54
TABLE 25 CANADA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 55
TABLE 26 CANADA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 56
TABLE 27 EUROPE LANCET MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 57
TABLE 28 EUROPE WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 58
TABLE 29 EUROPE WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 59
TABLE 30 EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 60
TABLE 31 GERMANY WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 60
TABLE 32 GERMANY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 61
TABLE 33 GERMANY WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 62
TABLE 34 FRANCE WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 62
TABLE 35 FRANCE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 63
TABLE 36 FRANCE WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 64
TABLE 37 UK WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 64
TABLE 38 UK WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 65
TABLE 39 UK WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 66
TABLE 40 ITALY WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 66
TABLE 41 ITALY WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 67
TABLE 42 ITALY WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 68
TABLE 43 SPAIN WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 68
TABLE 44 SPAIN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 69
TABLE 45 SPAIN WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 70
TABLE 46 REST OF EUROPE WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 70
TABLE 47 REST OF EUROPE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 71
TABLE 48 REST OF EUROPE WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 72
TABLE 49 ASIA-PACIFIC LANCET MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 73
TABLE 50 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 74
TABLE 51 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 75
TABLE 52 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 76
TABLE 53 JAPAN WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 76
TABLE 54 JAPAN WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 77
TABLE 55 JAPAN WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 78
TABLE 56 CHINA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 78
TABLE 57 CHINA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 79
TABLE 58 CHINA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 80
TABLE 59 INDIA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 80
TABLE 60 INDIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 81
TABLE 61 INDIA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 82
TABLE 62 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 83
TABLE 63 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 84
TABLE 64 REPUBLIC OF KOREA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 85
TABLE 65 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 86
TABLE 66 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 87
TABLE 67 REST OF ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 88
TABLE 68 MIDDLE EAST & AFRICA LANCET MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 89
TABLE 69 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 90
TABLE 70 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 91
TABLE 71 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 92
TABLE 72 UAE WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 93
TABLE 73 UAE WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 94
TABLE 74 UAE WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 95
TABLE 75 SAUDI ARABIA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 95
TABLE 76 SAUDI ARABIA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 96
TABLE 77 SAUDI ARABIA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 97
TABLE 78 EGYPT WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 97
TABLE 79 EGYPT WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 98
TABLE 80 EGYPT WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 99
TABLE 81 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY INDICATION, 2023-2030 (USD MILLION) 100
TABLE 82 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 101
TABLE 83 REST OF MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 102
TABLE 84 AMGEN: KEY DEVELOPMENT 109
TABLE 85 ELI LILLY COMPANY : KEY DEVELOPMENT 119
TABLE 86 PFIZER: PRODUCT OVERVIEW 124
TABLE 87 PFIZER: KEY DEVELOPMENTS 126
TABLE 88 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS 130
13 List Of Figures
FIGURE 1 GLOBAL WOMEN HEALTHCARE MARKET: MARKET STRUCTURE 17
FIGURE 2 RESEARCH PROCESS 18
FIGURE 3 GLOBAL WOMEN HEALTHCARE MARKET: PORTERS FIVE FORCES MODEL 25
FIGURE 4 GLOBAL WOMEN HEALTHCARE MARKET: VALUE CHAIN ANALYSIS 27
FIGURE 5 GLOBAL WOMEN HEALTHCARE MARKET, BY INDICATION, 2023-2030 (USD MILLION) 30
FIGURE 6 GLOBAL WOMEN HEALTHCARE MARKET, BY DIAGNOSIS & TREATMENT, 2023-2030 (USD MILLION) 38
FIGURE 7 GLOBAL WOMEN HEALTHCARE MARKET, BY END USER, 2023-2030 (USD MILLION) 42
FIGURE 8 GLOBAL WOMEN HEALTHCARE MARKET, BY REGION, 2023-2030 (USD MILLION) 48
FIGURE 9 NORTH AMERICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2020 (%) 49
FIGURE 10 EUROPE WOMEN HEALTHCARE MARKET, BY COUNTRY, 2020 (%) 58
FIGURE 11 ASIA-PACIFIC WOMEN HEALTHCARE MARKET, BY COUNTRY, 2020 (%) 74
FIGURE 12 MIDDLE EAST & AFRICA WOMEN HEALTHCARE MARKET, BY COUNTRY, 2020 (%) 89
FIGURE 13 GLOBAL WOMEN HEALTHCARE MARKET: COMPETITIVE LANDSCAPE 103
FIGURE 14 ALLERGAN PLC: FINANCIAL REVENUE 105
FIGURE 15 ALLERGAN PLC: SEGMENTAL REVENUE 105
FIGURE 16 AMGEN: RECENT FINANCIAL 108
FIGURE 17 AMGEN: GEOGRAPHIC REVENUE MIX 108
FIGURE 18 AMGEN: SWOT ANALYSIS 109
FIGURE 19 BAYER AG: FINANCIAL REVENUE 110
FIGURE 20 BAYER AG: SEGMENTAL REVENUE 111
FIGURE 21 BAYER AG: GEOGRAPHICAL REVENUE 111
FIGURE 22 BAYER AG: SWOT ANALYSIS 112
FIGURE 23 BECTON, DICKINSON AND COMPANY: FINANCIAL REVENUE 113
FIGURE 24 BECTON, DICKINSON AND COMPANY: SEGMENTAL REVENUE 114
FIGURE 25 BECTON, DICKINSON AND COMPANY: GEOGRAPHICAL REVENUE 114
FIGURE 26 BECTON, DICKINSON & COMPANY: SWOT ANALYSIS 116
FIGURE 27 ELI LILLY COMPANY : RECENT FINANCIAL 118
FIGURE 28 ELI LILLY COMPANY : BUSINESS REVENUE MIX (2015) 118
FIGURE 29 ELI LILLY COMPANY : GEOGRAPHIC REVENUE MIX 119
FIGURE 30 ELI LILLY COMPANY : SWOT ANALYSIS 120
FIGURE 31 MERCK & CO., INC.: FINANCIAL REVENUE 121
FIGURE 32 MERCK & CO., INC.: SEGMENTAL REVENUE 122
FIGURE 33 MERCK & CO., INC.: GEOGRAPHIC REVENUE 122
FIGURE 34 PFIZER: FINANCIAL REVENUE 125
FIGURE 35 PFIZER: SEGMENTAL REVENUE 125
FIGURE 36 PFIZER: GEOGRAPHIC REVENUE 126
FIGURE 37 PFIZER: SWOT ANALYSIS 127
FIGURE 38 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT FINANCIALS 128
FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL MIX, 2020 (%) 129
FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD: OPERATING SEGMENTS, 2020 (%) 129
FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS 131
